Table 2.
Antibiotics | Present study (2012–14) | Lynch et al7 (2009) | Krishan et al8 (2009) | Nagshetty et al5 (2010) | Chaudhary et al9 (2013) |
---|---|---|---|---|---|
Ampicillin | 42/46 (91.30%) | 1744/2016 (86.50%) | 42/50 (84%) | 67/95 (70.53%) | 290/322 (90.68%) |
Ceftriaxone | 43/46 (93.47%) | – | 50/50 (100%) | 89/95 (93.69%) | 322/322 (100%) |
Nalidixic acid | 23/46 (50%) | 1258/2016 (62.40%) | – | 65/95 (68.42%) | 26/322 (8.07%) |
Ciprofloxacin | 35/46 (76.80%) | 1282/2016 (63.59%) | 17/21 (81%) | 91/95 (95.78%) | 175/322 (54.34%) |
Chloramphenicol | – | 1744/2016 (86.50%) | 29/50 (58%) | 68/95 (71.57%) | 322/322 (100%) |
Cotrimoxazole | 42/46 (91.30%) | 1744/2016 (86.50%) | 44/50 (88%) | 78/95 (82.10%) | 306/322 (95.03%) |
Imipenem | 46/46 (100%) | – | – | 95/95 (100%) | – |